Modality
Radioligand
MOA
FGFRi
Target
HER2
Pathway
Innate Imm
MigrainePV
Development Pipeline
Preclinical
~Jul 2013
→ ~Oct 2014
Phase 1
~Jan 2015
→ ~Apr 2016
Phase 2
~Jul 2016
→ ~Oct 2017
Phase 3
~Jan 2018
→ ~Apr 2019
NDA/BLA
~Jul 2019
→ ~Oct 2020
Approved
Jan 2021
→ Dec 2029
ApprovedCurrent
NCT05172333
2,571 pts·Migraine
2024-07→2026-08·Terminated
NCT06552965
400 pts·Migraine
2021-01→2029-12·Completed
NCT07125764
398 pts·PV
2021-05→2027-07·Recruiting
+1 more trial
5,064 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-08-144mo awayPh3 Readout· Migraine
2027-07-121.3y awayPh3 Readout· PV
2029-12-153.7y awayPh3 Readout· Migraine
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Complet…
Approved
Recruit…
Approved
Not yet…
Approved
Termina…
Catalysts
Ph3 Readout
2026-08-14 · 4mo away
Migraine
Ph3 Readout
2027-07-12 · 1.3y away
PV
Ph3 Readout
2029-12-15 · 3.7y away
Migraine
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05172333 | Approved | Migraine | Terminated | 2571 | NT-proBNP |
| NCT06552965 | Approved | Migraine | Completed | 400 | FEV1 |
| NCT07125764 | Approved | PV | Recruiting | 398 | PFS |
| NCT08496948 | Approved | PV | Not yet recr... | 1695 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| ELV-1411 | Enliven | NDA/BLA | HER2 | |
| VYG-2970 | Voyager | Phase 3 | JAK1 |